News

OnCore would continue as a subsidiary of Tekmira, and the licensing agreement for NVP018 between NeuroVive and OnCore will remain in force following the merger as the combined

If approved, paliperidone palmitate will be the first and only long-acting atypical antipsychotic that has a dosing schedule of just four times a year. Schizophrenia is a complex

The approval follows an expedited review and positive opinion issued by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in November 2014. In

In order to further develop several series of Orexin-1 selective inhibitors, Evotec will apply its drug discovery platform with C4XD. Activation of the orexin-1 receptor in the brain

Cosentyx 300mg is the first and only interleukin-17A (IL-17A) inhibitor to be approved in Europe providing a new first-line biologic treatment option for these patients. At present, all

This relationship will allow Abattis Bioceuticals Corp the exclusive license for Cannabidiol rich hemp oil products delivered directly to licensed physicians and dispensaries. Empirical Labs is a high

Results from both studies were presented today at the 2015 Gastrointestinal Cancers Symposium in San Francisco, Calif. VT-122 is a novel, chrono-modulated combination of the non-selective beta-adrenergic receptor

The data, presented at the 2015 Gastrointestinal Cancers Symposium in San Francisco, Calif., point toward potential therapeutic options beyond standard-of-care immunomodulatory agents and pan-HER inhibitors for patients with

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that stimulates the secretion of insulin from the pancreas. Exenatide, a GLP-1 analog, is currently marketed in injectable form only, and